Opinion
Video
Future Insights on Bispecific Therapies
Experts discuss future directions for understanding the role of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL) treatment paradigms and research possibilities.
This is a video synopsis/summary of a Practice Pearls involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; Robert Mancini, PharmD; and Amir Ali, PharmD, BCOP, FHOPA.
In this segment, Mahmoudjafari and Ali discuss counseling patients and health care team collaboration regarding bispecific therapies, recognizing gaps due to their recent approval in May 2023. Ali notes ongoing discussions on sequencing therapies, especially with the potential durable remissions seen with chimeric antigen receptor T-cell therapy.
Looking ahead, Mancini envisions future developments, emphasizing exploring new targets, selecting specific products for patients based on response rates, and anticipating the shift of these therapies in the treatment sequence. Mancini also highlights the exploration of fixed-duration therapy and the need for more data on toxicity, particularly cytokine release syndrome and neurotoxicities.
Despite concerns, Mancini believes there might be more trepidation than necessary, and experience could alleviate provider hesitancy. Overall, the segment emphasizes ongoing discussions, future research directions, and the importance of exploring toxicity and treatment paradigms to enhance patient outcomes.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
